Evidence map›Paper›PMID 31531182›Full record

ArticleOxidative medicine and cellular longevity2019

Carvacrol and Thymol Modulate the Cross-Talk between TNF-

Yasmen F Mahran, Amira M Badr, Alhanouf Aldosari, Raghad Bin-Zaid, Hind N Alotaibi

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Natural Guardians: Natural Compounds as Radioprotectors in Cancer Therapy.International journal of molecular sciences · 2024
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Research Progress of PCNA in Reproductive System Diseases.Evidence-based complementary and alternative medicine : eCAM · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Yasmen F MahranDepartment of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.ORCID https://orcid.org/0000-0002-6306-5616
Amira M BadrDepartment of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.ORCID https://orcid.org/0000-0003-3983-868X
Alhanouf AldosariCollege of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 114592, Saudi Arabia.
Raghad Bin-ZaidCollege of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 114592, Saudi Arabia.
Hind N AlotaibiDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 114592, Saudi Arabia.
King Saud University · SAAin Shams University · EGPrincess Nourah bint Abdulrahman University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Premature ovarian failure (POF) is a common cause of infertility in premenopausal women who are unavoidably exposed to cytotoxic therapy. Radiotherapy is one of the most effective cytotoxic treatments. However, the radiosensitivity of ovarian tissues limits its therapeutic outcome and results in the depletion of the primordial follicle and loss of fertility. Therefore, the need for an effective radioprotective therapy is evident especially when none of the current clinically used modalities for radioprotection succeeds efficiently. The present study investigated the potential radioprotective effect of carvacrol (CAR) (80 mg) or thymol (80 mg) on gamma- (

Indexed as

Signal TransductionAnimalsCymenesFemaleGamma RaysInsulin-Like Growth Factor IPrimary Ovarian InsufficiencyRadiation-Protective AgentsRadiotherapyRatsRats, WistarThymolTumor Necrosis Factor-alphacarvacrolCymenesinsulin-like growth factor-1, ratInsulin-Like Growth Factor IRadiation-Protective AgentsThymolTumor Necrosis Factor-alpha

Identifiers

PMID31531182
PMCPMC6721489
OpenAlexW2969328838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.